{"id":20318,"date":"2022-10-06T09:39:35","date_gmt":"2022-10-06T13:39:35","guid":{"rendered":"https:\/\/medicarereport.org\/?p=20318"},"modified":"2022-10-06T09:39:36","modified_gmt":"2022-10-06T13:39:36","slug":"a-new-drug-for-a-relentless-brain-disease","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=20318","title":{"rendered":"A New Drug For A Relentless Brain Disease"},"content":{"rendered":"\n<p>(By Jon Hamilton and Thomas Lu for NPR on October 5, 2022)<\/p>\n\n\n\n<p>ALS is a disease that gradually destroys the nerve cells in the brain and spinal cord we need for voluntary movement. Most people diagnosed with amyotrophic lateral sclerosis, also known as Lou Gehrig&#8217;s disease, die within two to five years of diagnosis. <a href=\"https:\/\/www.npr.org\/2022\/10\/04\/1126740886\/a-new-drug-for-a-relentless-brain-disease\"> here&#8230;<\/a>  <\/p>\n\n\n\n<p> <img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"54\" class=\"wp-image-3902\" style=\"width: 150px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>&nbsp;The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Jon Hamilton and Thomas Lu for NPR on October 5, 2022) ALS is a disease that gradually destroys the<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18,12,48,15],"tags":[92,122,159,147],"class_list":["post-20318","post","type-post","status-publish","format-standard","hentry","category-aging","category-health-care-general","category-mental-healthbehavioral-health","category-part-dprescription-drugs","tag-aging","tag-als","tag-brain-disease","tag-pharmaceutical"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/20318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20318"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/20318\/revisions"}],"predecessor-version":[{"id":20319,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/20318\/revisions\/20319"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}